Key Takeaways
- Adult-use cannabis remains classified as Schedule I federally, creating ongoing contradictions with state legal markets.
- Recent changes moved certain cannabis products to Schedule III, recognizing their medical value but not affecting adult-use cannabis.
- The upcoming June 29 DEA hearing could determine if marijuana as a whole moves to Schedule III, offering potential benefits to operators.
- While Schedule III could ease some burdens, it won’t legalize adult-use cannabis or eliminate the existing regulatory complexities.
- The split between medical and adult-use cannabis remains a policy mess, complicating compliance and creating unfair burdens for smaller operators.
For years, the cannabis industry has been forced to live inside one of the most absurd contradictions in American law. States license cannabis businesses. States tax them. States inspect them, regulate them, and depend on them for jobs and revenue. Meanwhile, the federal government still treats much of that same activity like criminal conduct, largely because Adult-use cannabis remains on a Schedule I classification.
Now that contradiction has gotten even messier.
Certain cannabis products have been moved into Schedule III under federal law. That includes FDA-approved marijuana products and marijuana regulated under qualifying state medical cannabis licenses. That shift matters. It is an overdue acknowledgment that cannabis has accepted medical value, no matter how long federal policy tried to deny what patients, caregivers, doctors, and operators have known for decades.
But let’s not confuse movement with freedom.
Adult-use cannabis is still Schedule I.
That means recreational cannabis sold legally in licensed dispensaries across the nation is still being treated under federal law as if it belongs in the same category reserved for substances with no accepted medical use. That is not just outdated. It is dishonest.
And that is why the DEA’s administrative hearing scheduled for June 29th matters so much. It could determine whether marijuana as a whole moves from Schedule I to Schedule III. If that happens, adult-use operators could finally see some relief from one of the most broken federal frameworks ever imposed on a legitimate industry. If it does not, we stay stuck in the same split system, where medical cannabis gets partial recognition while adult-use cannabis keeps carrying the full weight of federal prohibition.
From where we sit, that is still not good enough.
Medical Cannabis Got a Federal Upgrade
The recent federal action moved two categories into Schedule III: FDA-approved marijuana drug products, and marijuana regulated under qualifying state medical cannabis licenses.
That is a real development, especially for medical operators who may now have a path toward federal compliance and relief from some of the punitive tax rules that have crushed this industry for years. The biggest issue here is Section 280E of the Internal Revenue Code, which bars businesses trafficking in Schedule I or II substances from deducting ordinary business expenses.
For cannabis companies, 280E has been a financial sledgehammer. It has punished businesses for paying rent, covering payroll, investing in security, buying software, hiring professionals, marketing responsibly, and doing all the ordinary things legitimate businesses need to do to survive. If a medical cannabis business now qualifies under Schedule III, that tax burden could ease in a very meaningful way.
That is real money. Real cash flow. Real breathing room.
But let’s call it what it is: limited relief for a limited category.
Adult-use operators did not get the same break. They are still dealing with Schedule I treatment, continued 280E exposure, continued federal illegality, continued banking complications, and continued uncertainty. So yes, some of the industry just moved forward. But a massive part of it is still chained to the same failed federal logic.
Adult-Use Cannabis Is Still Federally Illegal
Adult-use cannabis did not become federally legal. It did not even become federally tolerated in any meaningful statutory sense. Any marijuana product not covered by FDA approval or a qualifying medical marijuana license remains Schedule I. That includes flower, edibles, concentrates, pre-rolls, vape products, tinctures, infused beverages, topicals, and pretty much every other adult-use product sold in licensed state markets.
That means legal adult-use operators are still stuck in the same federal box they were in before.
It also means consumers are still stuck with the same risks and confusion. State legality does not erase federal consequences in areas like immigration, federal employment, firearms, travel, federal housing, or veterans’ issues. If you are an adult-use consumer, the federal government still has not caught up to the reality on the ground.
That reality, by the way, is already obvious. Millions of adults use cannabis. State-regulated markets are operating in plain sight. Businesses are creating jobs and paying taxes. Communities are counting on that revenue. Consumers are buying tested products in licensed stores instead of underground markets. The federal government is not preserving order here. It is lagging behind it.
Why the June 29th DEA Hearing Is a Big Deal
The DEA hearing is the next major checkpoint.
This proceeding is set to consider whether marijuana as a whole should be moved from Schedule I to Schedule III. If that happens, adult-use cannabis operators could gain access to tax relief, stronger institutional legitimacy, expanded research opportunities, and some reduction in the federal stigma that has haunted the industry for generations.
But nobody should pretend Schedule III is some magical end point.
It is not legalization. It is not interstate commerce. It is not full banking reform. It is not a clean national market. It is not automatic fairness for small operators. And it is definitely not descheduling.
Still, it would matter. Moving all marijuana out of Schedule I would be the clearest federal acknowledgment yet that cannabis does not belong in the most restrictive category under the Controlled Substances Act. That matters for policy. It matters for business. It matters for science. It matters for culture.
The real question is whether federal officials are ready to take one honest step, or whether they will keep clinging to a fiction nobody in the regulated market believes anymore.
Schedule III Could Help, But It Could Also Create a New Maze
Let’s be honest about both sides of this.
If adult-use cannabis moves to Schedule III, many businesses could finally escape 280E. That alone could transform the economics of the legal market. Operators could reinvest in people, compliance, product quality, education, expansion, and stability instead of bleeding cash into a tax structure built to punish them.
Research could also improve. Schedule I has long made cannabis science harder than it needed to be. A broader Schedule III classification could make it easier to study cannabinoids, terpenes, formulations, safety, efficacy, and health outcomes. That would be a win for patients, consumers, clinicians, and policymakers.
Capital markets might also respond. Investors, lenders, insurers, and payment providers have spent years pricing federal risk into every cannabis deal. Less risk does not mean no risk, but it could help unlock capital and reduce some of the drag that has kept the industry unstable.
Now the other side.
Schedule III still keeps cannabis inside the Controlled Substances Act. That means more regulation, more gatekeeping, more interpretation fights, and more opportunities for federal agencies to build systems that favor the biggest players. We have already made this point loudly in Rescheduling Is Not Freedom: Why Moving Cannabis to Schedule III Fails Justice Reform. A pharmaceutical-style framework may be manageable for giant corporations with deep legal teams and endless capital. It is a different story for legacy operators, family-run companies, social equity licensees, and smaller brands that built this industry before the suits showed up.
That is why descheduling remains the better answer. Remove cannabis from the Controlled Substances Act altogether, and you avoid forcing this plant into a federal structure that was never built to handle it honestly in the first place.
The Medical vs. Adult-Use Split Is a Policy Mess
The current split between medical and adult-use cannabis may look neat in legal language, but it falls apart quickly in the real world.
Some businesses serve both markets. Some facilities produce for both channels. Some states have merged supply chains or built systems where the operational line between medical and adult-use is not nearly as clean as federal policy wants to pretend. Some consumers buy adult-use products for medical reasons because they cannot access a card, cannot afford the process, or live in a state where the medical system is too limited.
So now we have a two-tier federal setup. One product might qualify for Schedule III in one transaction and remain Schedule I in another, even if the product is nearly identical. That is not efficient. That is not smart regulation. That is a compliance headache waiting to become a litigation festival.
It also raises a deeper concern. If relief only flows to medical cannabis, smaller adult-use operators, including many social equity businesses, may be left carrying the heaviest regulatory and tax burdens. That is not reform. That is selective relief.
Why This Is Bigger Than Taxes
Yes, 280E matters. A lot.
But the bigger issue is whether the federal government is finally ready to stop pretending cannabis has no accepted place in American life. The public moved on a long time ago. States moved on. Patients moved on. Consumers moved on. Federal law is the one still acting like it is 1970.
As we noted in our own coverage, including Nixon’s Buried Marijuana Report and the Modern Fight Over Rescheduling vs. Descheduling Cannabis, this debate is not new. The evidence has been here. The politics have just kept getting in the way.
And if public opinion is the test, the answer is already clear. We recently covered data showing broad public support for legalization in Pew Poll Shows 88% of Americans Support Cannabis Legalization. The country is not waiting for permission anymore. Washington is just late to the party.
Rescheduling Is a Step. Descheduling Is the Destination.
We can walk and chew gum here.
If the DEA extends Schedule III to all marijuana, that would be meaningful progress. It would help operators. It would support research. It would weaken some of the most irrational parts of federal cannabis policy.
But we should not let anyone sell that as the finish line.
Rescheduling is a policy adjustment. Descheduling is the end of federal prohibition. That is the difference between editing the problem and actually solving it.
Cannabis should not be trapped inside a framework that was built on fear, politics, and misinformation. It should be removed from the CSA altogether and regulated in ways that make sense for public health, consumer safety, business integrity, and state autonomy.
Anything less is still compromise with a failed system.
Frequently Asked Questions
No. Adult-use cannabis remains federally illegal and is still classified as Schedule I unless it falls within a qualifying medical marijuana license category or an FDA-approved product category.
Only in part. FDA-approved marijuana products and marijuana regulated under qualifying state medical cannabis licenses moved to Schedule III. Adult-use cannabis remains Schedule I for now.
The DEA is set to begin an administrative hearing to consider whether marijuana as a whole should move from Schedule I to Schedule III under federal law.
No. Schedule III would not fully legalize cannabis. It would reduce some federal burdens and acknowledge medical value, but cannabis would still remain controlled under the Controlled Substances Act.
Section 280E prevents businesses trafficking in Schedule I or II substances from deducting ordinary business expenses. If cannabis moves to Schedule III, qualifying operators may no longer be subject to 280E, which could significantly improve margins and stability.
Rescheduling moves cannabis from one schedule to another within the Controlled Substances Act. Descheduling removes cannabis from the Controlled Substances Act entirely. Rescheduling is partial reform. Descheduling is the actual end of federal prohibition.
